gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · JAZZHealthcarePharmaceuticals

Jazz Pharmaceuticals, Inc. (JAZZ)

$234.66+2.14%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$234.66▲ 70.27% in range
Nov 4, 2025Low $131.16 · High $261.62Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Jazz Pharmaceuticals closed at $234.66 on Nov 4, up 2.14%, 10.3% below its 52-week closing high. Volume of 899.1K shares was 1.02× its 20-day average (close to normal).

Split-adjusted performance: +1.4% over one month, +2.7% over six months, +69.6% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.24B, up 10.4% from a year earlier, with a net margin of -38.9%.

Short interest was 5.9M shares at the Oct 15 settlement, up 7.0% from the prior report (9.4% of float, 6.9 days to cover).

Market cap$15.23B64.9M shares
Revenue · quarter$1.24B+10.4% YoY
Diluted EPS$-7.48−283.3% YoY
P/E · TTM74.0×P/S 3.2×
Net margin-38.9%Gross 91.1%
Dividend yieldNone
52-week range131.16 – 261.62−10.3% from high
Volume899.1K1.02× 20-day avg
Volatility · 60d31.2%Annualised
Short % of float9.4%6.9 days to cover
Net cash-$2.71BCash $2.86B
Next earnings—Not scheduled
Split-adjusted performance
1W +14.4%1M +1.4%3M −8.6%6M +2.7%YTD +38.0%1Y +69.6%3Y +87.8%5Y +75.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum74
Revenue growth57
Net margin49
Value (low P/E)14
Size96

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.9M+7.0% vs prior
Days to cover6.9Settled Oct 15
% of float9.4%
Short vol. 10d61.7%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
JAZZJazz Pharmaceuticals$234.66+2.14%+2.7%+10.4%−38.9%74.0$15.23B
BBIOBridgeBio Pharma$77.89+5.21%+14.4%+192.6%−23.5%—$15.17BCompare
SMMTSummit Therapeutics$16.17+2.34%−9.4%———$12.90BCompare
ELANElanco Animal Health Incorporated$25.31+3.01%−3.3%+10.2%3.9%—$12.65BCompare
BMRNBioMarin Pharmaceuticals$57.13+2.64%+4.6%+19.9%4.5%151.5$11.06BCompare
ALNYAlnylam Pharmaceuticals$161.08+0.74%−46.8%+16.7%148.6%7.9$21.57BCompare
VTRSViatris$19.22+1.59%+20.5%+4.9%−3.2%—$22.08BCompare
INSMInsmed$110.00+5.32%−19.8%+268.4%−19.1%—$24.13BCompare
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43BCompare

News about Jazz Pharmaceuticals

All news →
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research · 2d ago▼ NegativeAnalysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out forZacks Investment Research · Oct 26, 2026▼ NegativeHere's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value StockZacks Investment Research · Oct 6, 2026▲ PositiveShould You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?The Motley Fool · Sep 18, 2026▲ PositiveWhy Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?Zacks Investment Research · Sep 2, 2026▲ Positive

Quick answers

What does Jazz Pharmaceuticals do?
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia.
What is JAZZ's market cap?
$15.23B, based on the Nov 4 close of $234.66.
What is JAZZ's P/E ratio?
74.0× trailing-twelve-month earnings of $205.95M.
Does Jazz Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of JAZZ is sold short?
5.9M shares, 9.4% of float, as of Oct 15, 2026.
What sector is JAZZ in?
Healthcare, in the Pharmaceuticals industry.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

HQ: Dublin, 2,890 employeesListed Jun 1, 2007jazzpharmaceuticals.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology